Document is current
Any future updates will be listed below
-
Authors
Steele, Lloyd
Olabi, Bayanne
Roberts, Kenny https://orcid.org/0000-0001-6155-0821
Mazin, Pavel V. https://orcid.org/0000-0001-9268-3352
Koplev, Simon https://orcid.org/0000-0002-8586-5614
Tudor, Catherine
Rumney, Benjamin
Admane, Chloe
Jiang, Treasa
Correa-Gallegos, Donovan
Chakala, Keerthi Priya https://orcid.org/0009-0008-1071-8629
Binkevich, Aljes https://orcid.org/0009-0003-1467-1606
Gopee, Nusayhah Hudaa https://orcid.org/0000-0001-8507-5682
Predeus, Alexander https://orcid.org/0000-0002-2750-1599
Prete, Martin
Winheim, Elena https://orcid.org/0000-0002-0364-662X
Annusver, Karl
Forsthuber, Agnes https://orcid.org/0000-0001-6396-0090
Francis, Luc
Frech, Sophie
Ganier, Clarisse
Layton, Thomas
Liu, Yingzi https://orcid.org/0000-0002-8704-4756
Yuan, Hao
Gudjonsson, Johann E. https://orcid.org/0000-0002-0080-0812
Lichtenberger, Beate M. https://orcid.org/0000-0001-6882-0257
Mahil, Satveer https://orcid.org/0000-0003-4692-3794
Nanchahal, Jagdeep https://orcid.org/0000-0002-9579-9411
O’Toole, Edel A.
Plikus, Maksim V. https://orcid.org/0000-0002-8845-2559
Rinkevich, Yuval
Rognoni, Emanuel
Smith, Catherine H. https://orcid.org/0000-0001-9918-1144
Teichmann, Sarah A. https://orcid.org/0000-0002-6294-6366
Kasper, Maria https://orcid.org/0000-0002-6117-2717
Foster, April R. https://orcid.org/0000-0002-5397-4365
Lotfollahi, Mohammad
Haniffa, Muzlifah https://orcid.org/0000-0002-3927-2084
-
Funding
Funding for this research was provided by:
Wellcome Trust (220540/Z/20/A)
- License Information
-
More Information
Article History
Received: 9 December 2024
Accepted: 5 August 2025
First Online: 24 September 2025
Competing interests
: S.A.T. is a scientific advisory board member of ForeSite Labs, OMass Therapeutics, Qiagen, Xaira Therapeutics, a cofounder and equity holder of TransitionBio and Ensocell Therapeutics, a non-executive director of 10x Genomics and a part-time employee of GlaxoSmithKline. M.L. owns interests in Relation Therapeutics and is a scientific cofounder and part-time employee at AIVIVO. S.K.M. reports departmental income from AbbVie, Almirall, Eli Lilly, Janssen-Cilag, Leo Pharma, Novartis, Pfizer, Sanofi and UCB, outside the submitted work. C.H.S. reports grants from a Medical Research Council-funded stratified medicine consortium with multiple industry partners (PSORT.org), grants from IMI (Horizon 2020)-funded European consortium with multiple industry partners (BIOMAP-IMI.eu, HIPPOCRATES-IMI.eu, grants from Open Targets (Wellcome Sanger Institute), and others from AbbVie, Novartis, Pfizer, Sanofi, Boehringer Ingelheim and Swedish Orphan Biovitrum, outside the submitted work; and is Chair of UK guidelines on biologic therapy in psoriasis. The other authors declare no competing interests.
